Literature DB >> 32471814

Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Should Type of ANCA Guide the Treatment?

Vladimir Tesar1, Zdenka Hruskova2.   

Abstract

Entities:  

Keywords:  ANCA; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies; Antineutrophil Cytoplasmic; vasculitis

Year:  2020        PMID： 32471814      PMCID： PMC7536742          DOI： 10.2215/CJN.15861219

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

1.  Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Michael Walsh; Oliver Flossmann; Annelies Berden; Kerstin Westman; Peter Höglund; Coen Stegeman; David Jayne
Journal:  Arthritis Rheum       Date:  2012-02

2.  Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.

Authors:  Sebastian Unizony; Miguel Villarreal; Eli M Miloslavsky; Na Lu; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cg M Kallenberg; E William St Clair; David Ikle; Nadia K Tchao; Linna Ding; Paul Brunetta; Hyon K Choi; Paul A Monach; Fernando Fervenza; John H Stone; Ulrich Specks
Journal:  Ann Rheum Dis       Date:  2015-11-30       Impact factor: 19.103

3.  Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum.

Authors:  Alfred Mahr; Ulrich Specks; David Jayne
Journal:  Rheumatology (Oxford)       Date:  2019-10-01       Impact factor: 7.580

4.  Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.

Authors:  Sophia Lionaki; Elizabeth R Blyth; Susan L Hogan; Yichun Hu; Brent A Senior; Caroline E Jennette; Patrick H Nachman; J Charles Jennette; Ronald J Falk
Journal:  Arthritis Rheum       Date:  2012-10

5.  Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

Authors:  Lorraine Harper; Matthew D Morgan; Michael Walsh; Peter Hoglund; Kerstin Westman; Oliver Flossmann; Vladimir Tesar; Phillipe Vanhille; Kirsten de Groot; Raashid Luqmani; Luis Felipe Flores-Suarez; Richard Watts; Charles Pusey; Annette Bruchfeld; Niels Rasmussen; Daniel Blockmans; Caroline O Savage; David Jayne
Journal:  Ann Rheum Dis       Date:  2011-11-29       Impact factor: 19.103

6.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

7.  Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Authors:  Alexandre Karras; Christian Pagnoux; Marion Haubitz; Kirsten de Groot; Xavier Puechal; Jan Willem Cohen Tervaert; Mårten Segelmark; Loic Guillevin; David Jayne
Journal:  Ann Rheum Dis       Date:  2017-05-25       Impact factor: 19.103

8.  Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  E M Miloslavsky; U Specks; P A Merkel; P Seo; R Spiera; C A Langford; G S Hoffman; C G M Kallenberg; E W St Clair; N K Tchao; L Viviano; L Ding; L P Sejismundo; K Mieras; D Iklé; B Jepson; M Mueller; P Brunetta; N B Allen; F C Fervenza; D Geetha; K Keogh; E Y Kissin; P A Monach; T Peikert; C Stegeman; S R Ytterberg; J H Stone
Journal:  Arthritis Rheum       Date:  2013-09

9.  Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.

Authors:  Anoek A E de Joode; Jan Stephan F Sanders; Xavier Puéchal; Loic P Guillevin; Thomas F Hiemstra; Oliver Flossmann; Nils Rasmussen; Kerstin Westman; David R Jayne; Coen A Stegeman
Journal:  Rheumatology (Oxford)       Date:  2017-11-01       Impact factor: 7.580

10.  Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis.

Authors:  Michael Walsh; Mikkel Faurschou; Annelies Berden; Oliver Flossmann; Ingeborg Bajema; Peter Hoglund; Rona Smith; Wladimir Szpirt; Kerstin Westman; Charles D Pusey; David R W Jayne
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-26       Impact factor: 8.237
  10 in total
  1 in total

Review 1.  Proposal for a more practical classification of antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Nestor Oliva-Damaso; Andrew S Bomback
Journal:  Clin Kidney J       Date:  2020-12-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.